Preventive and Therapeutic Vaccines Against HIV: From New Mechanisms to Clinical Trials

1. Introduction

According to UNAIDS, at the end of 2024, despite the changes brought about by the COVID-19 epidemic, the number of people living with HIV in the world was 39 million. In 2023, the number of new HIV infection cases was more than 1.3 million. More than 630,000 people died from opportunistic infections associated with AIDS in 2022. At the same time, by the end of 2023, more than 40.4 million AIDS patients have died worldwide since the first cases of infection were recorded in 1981 [1,2].

The problem of HIV infection is still far from being resolved. However, the increasingly available HIV serodiagnosis, combined with highly active antiretroviral therapy, has halted the spread of the epidemic and prolonged the lives of infected patients, making the highly lethal disease a chronic one. However, the ongoing treatment does not solve the problems of multiple drug resistance (MDR) formation, low compliance, and high cost [3,4]. More virulence and drug-resistant subtypes and circulating recombinant forms (CRF) of HIV are emerging [5,6]. Moreover, the problem of HIV-tuberculosis (TB) co-infection still remains relevant [7].

Until an effective vaccine is available, a comprehensive approach is needed in the fight against HIV infection and AIDS, using all possible means of therapy and prevention (involving all levels), including microbicides [8,9,10,11,12,13]. Moreover, studies clearly show that HIV prevention in high-risk groups is more cost-effective than therapy [13,14,15].

The development of antiretroviral drugs for the treatment of HIV has influenced the development of other antiviral drugs targeting different viruses. Some HIV drugs have served as a foundation for the development of drugs against other viral infections, e.g Based on HIV nucleoside reverse transcriptase, protease and integrase inhibitors other drugs for the treatment of Hepatitis C (HCV) infection were developed, such as sofosbuvir, telaprevir and bictegravir.

The development of a COVID-19 vaccine opens up opportunities for the development of an HIV vaccine, it can contribute to broader advancements in vaccine development and immunology. The development of COVID-19 vaccines has utilized various vaccine platform technologies, such as mRNA, viral vector, and protein subunit vaccines. These platforms can be adapted and applied to other viral diseases, including HIV. It is noteworthy that in 2023, Dr. Katalin Karikó and Dr. Drew Weissman were awarded the Nobel Prize in physiology or medicine due to their discoveries concerning nucleoside base modifications that eventually enabled the development of mRNA vaccines against COVID-19 [16]. They both hoped that mRNA vaccine technology will help create an effective anti-HIV vaccine. Lessons learned from the development of COVID-19 vaccines can help researchers explore and optimize similar platform technologies for HIV vaccine candidates.

The following comprehensive review covers some of the most exciting trials of prophylactic and therapeutic vaccines against HIV with a detailed description of the mechanism, entering a new milestone in their existence.

2. Structure, Protein Functions, and the Infectious Mechanisms of HIV

HIV, a single-stranded RNA-containing, enveloped, reverse transcribed virus of the Retroviridae family and genus Lentivirus, causes HIV infection, which in its terminal stage progresses to AIDS [17,18].

The subtypes of HIV include: HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 viruses can be further divided into groups M (major), N (new or non-M, non-O), O (outlier), and P. Most of the isolates belong to the M group, in which following subtypes are distinguished: A, B, C, D, F-1, F-2, G, H, J, K. While HIV-1 subtypes N, O, and P as well as HIV-2, have primarily been confined to West Africa, strains of HIV-1 group M have become ubiquitous [17,18,19,20,21,22,23].

The virion is spherical, 80-100 nm in size, covered on the outside with a shell formed during budding from the plasma membrane of the host cell. The envelope contains glycoprotein (gp) spikes consisting of surface gp120 and transmembrane gp41 (cleavage products of gp160 precursor protein). Beneath the shell are the p17 matrix protein, the p24 capsid protein, nucleoproteins (p7, and p9), as well as enzymes (reverse transcriptase - p51 / p66, integrase - p31-32 and protease - p10). The capsid contains two identical plus-strand copies of the RNA genome, which includes the structural genes gag, pol, env, etc. [24]. HIV-2 contains gp140, gp105, gp36, p26 proteins instead of HIV-1 proteins (gp120, gp41, gp160, p24). The structural elements of HIV should be considered as potential targets for vaccine candidates, which will be further discussed in this article (Figure 1).

2.1. HIV-1 Gene-Encoded Proteins and Their Functions

The HIV genome contains structural and regulatory genes. The structural genes include gag, pol, and env, while the regulatory genes can be divided into genes necessary for viral replication (rev, tat) and additional genes (nef, vif, vpr, vpu). A detailed description of the genes, the proteins they encode, and their respective functions is provided in Table 1 [17,25,26,27,28,29].

2.2. Mechanism of Infection

The virus binds via the glycoprotein gp120 to the CD4-T-helper receptor and cells of macrophage origin (macrophages, dendritic and microglial cells). The co-receptors for HIV are CCR5 and CXCR4 chemokine receptors on T-lymphocytes, monocytes, macrophages, Langerhans cells [43,44]. The majority of primary HIV-1 isolates in early disease use CCR5 as a coreceptor, whereas during disease progression with the emergence of syncytium-inducing viruses, CXCR4 is also used [45]. The gp120 comprises constant (C1-C4) and variable (V1-V5) regions, forming nine antigenic epitopes. The variable regions are prone to genetic mutations during the multi-stage replication process of the virus, which accounts for the high variability of HIV. HIV enters the cell by fusion of the envelope with the plasma membrane of the cell through the gp41. After deproteinization of the virion in the cytoplasm of the cell, complementary (proviral) DNA is synthesized on the RNA template using viral RT, which, as part of the preintegration complex, penetrates the nuclear membrane and integrates with the cell DNA using viral IN. The resulting DNA-provirus included in the chromosomal DNA can be latent or serve as the basis for the synthesis of viral genomic RNA and mRNA, which provide the synthesis and assembly of virions. Virions exit the cell by budding: the core of the virus "dresses" in the altered plasma membrane of the cell. If normally immune cells are activated, they begin to translate and transcribe the proteins necessary for the immune response, then in the presence of HIV in the body, infected immune cells facing any infection transcribe and translate new viruses that are cleaved from the cell membrane and infect more cells [17,18,19,20,21,22,46,47].

3. Vaccines Based on the Induction of Neutralizing Antibodies

Research into developing a vaccine against HIV began in 1986. The first trial used the assumption that activating the neutralizing antibodies would protect against a potential HIV infection. The first HIV vaccines were developed using recombinant DNA gene modification technology, which was similar to the hepatitis B vaccine licensed in 1986 [25,48,49]. From the period of 1988 to 2008, various HIV vaccine designs were developed around the viral envelope glycoproteins (mainly gp120 and gp160), which are responsible for binding the virus to the target cells and serve as the primary target for neutralizing antibodies. Among the first to begin testing was VaxSyn (1988-2003) a recombinant envelope glycoprotein (rgpl60) created in the baculovirus-insect cell system. Subsequently, numerous envelope proteins were assessed in additional 35 studies.

Collectively, these vaccine constructs induced binding and neutralizing antibodies, which were long-lasting, and also stimulated CD4+ T cell responses, but did not produce overt cytotoxic lymphocyte (CD8+ CTL) responses [50]. The induction of CTL responses, which was already perceived as a desirable characteristic of a HIV vaccine, could be achieved through the use of live vectors, especially poxvirus vectors [51]. Live vectors were found to be useful because they could simulate natural infection by presenting antigens to the immune system. Two different groups in 1986 reported the expression of the HIV envelope gene in vaccinia vectors [52,53].

One of them was HIVAC-1e (1988), a recombinant vaccinia virus designed to express HIV gp160. In the majority of subjects, the T-cell responses were transient and no antibodies to HIV were detected. However, the appearance of a sustained T-cell response in a small proportion of subjects led researchers to the idea that antibody responses would be enhanced by priming with a recombinant vaccinia vector expressing the HIV-1 envelope and then with an envelope booster protein [54]. VaxSyn + HIVAC-1e (1991) – combined approach. The prime-boosting approach enhanced both the humoral and cellular immune response and induced neutralizing antibodies [55,56]. At this stage, one of the features of the vector used became apparent: there was a marked decrease in the immunogenicity of the vector in individuals previously vaccinated against smallpox [49,54].

Of course, the further refusal to use the cowpox vector was largely influenced by the fact that the introduction of such a vaccine is contraindicated for people who already have immunosuppression, which means that its use is unsafe in groups at high risk of HIV infection [57,58]. It was decided to use non-replicating poxvirus vectors in the early 1990s, based on two models, namely, a highly attenuated strain of vaccinia virus (NYVAC) or an avian poxvirus, canarypox (ALVAC), that is not able to replicate in mammalian cells [51,59]. ALVAC-HIV vector vaccine, an HIV vaccine with the ALVAC vector, vCP125, expressing gp160 has been tested alone or as a combination primary booster with the gp160 subunit. The vaccine significantly stimulated the response of neutralizing antibodies to protein administration and induced CTL activity [60]. Other ALVAC vectors (vCP205, vCP300, vCP1433, vCP1452, and vCP1521) have been designed not only to express the HIV envelope, but also to express gag and other HIV genes to induce a broader cell-mediated immune response. It was vCP1521 that was then used in the most successful trial of RV144 [61,62]. Vax003-Vax004 ‒ (1994-) vaccines based on bivalent recombinant gp120 and alum provided protection to chimpanzees after HIV infection and were safe and immunogenic in phase 1/2 of human clinical trials [63,64]. As a result, high levels of both neutralizing antibodies (nAbs) binding (in VAX003 and VAX004) and antibody-dependent cellular inhibition of the virus (in VAX004) were observed, but both candidates were not effective in preventing HIV infection due to their narrow specificity[63,64].

3.1. Direct Cytotoxicity

Vaccines aimed at stimulating CTLs will cause pre-sensitized CTL to immediately recognize HIV-infected cells and destroy them by the mechanism of direct cytotoxicity, preventing further replication of the virus. The mechanism of the cytotoxic effect is described below and in Figure 2.

CTLs secrete perforin proteins, which are incorporated into the cell membrane and oligomerize therein to form a pore. Next, CTLs secrete granzyme B, which enters the cell through the previously created pore. The cell cytosol contains procaspase 7, which consists of prodomain, large subunit and small subunit. Granzyme B proteolytically detaches the prodomain procaspase from the large subunit and also detaches the large subunit from the small subunit. Two executioner procaspase 7 molecules are required to form an "active" caspase. As a result, the two large and two small procaspase subunits join together to form a heterotetramer, which is active executioner caspase 7. Executioner caspase 7 starts proteolytically destroying the cell proteins leading to cell death.

It is important to note that proapoptotic proteins such as Bax and Bak are constantly present in the cell. Moreover, Bak is built into the outer mitochondrial membrane and Bax is freely present in the cell cytoplasm. The Bax molecule oligomerizes with Bak on the outer mitochondrial membrane forming a large pore in it through which cytochrome c escapes from the intermembrane space into the cell cytosol and triggers apoptosis. However, in the normal cell cytoplasm there are anti apoptotic proteins such as Bcl2 and BCl-XL, which bind to Bax and Bak preventing their oligomerization. Granzyme B proteolytically destroys Bcl2 and BCl-XL proteins and thus creates conditions for cytochrome c release into the cell cytosol [65].

The cell cytosol contains Apoptotic protease activating factor 1 (APAF1) which has a caspase recruitment domain (CARD) that binds to the active center of APAF1 itself and blocks it. But cytochrome c, once in the cytosol of the cell, pushes CARD from the active center of APAF1 and binds itself to it instead of CARD. Further, about 7 APAF1 molecules with active centers bound by cytochrome c bind to each other using their own CARD domains, forming the apoptosome. Further, CARDs associated with the prodomain of seven initiator procaspase 9, interact with the CARDs that are part of the apoptosome. As a result of this interaction, the small subunit detaches from the large subunit of procaspase 9, and the large subunit also detaches from the prodomain. From there, a heterotetramer consisting of two large and two small subunits is assembled with the formation of the "active" initiator caspase 9, which itself will start proteolytically activating Caspase 3 and Caspase 6, which are the executioner caspases. Caspase 3 and Caspase 6 produce proteolysis of the cell proteins, which leads to cell death [66].

3.2. Chemokine-Mediated HIV Suppression

Chemokine based vaccines, especially CCL4 based vaccines, will lead to CCR5 desensitization. This would result in HIV having no entry gate for T-helper cells to be infected. Although this type of vaccines will not protect somatic cells from infection, they will prevent the development of AIDS. The mechanism of CCR5 desensitization is described below and in Figure 3.

Being a ligand for CCR5, CCL4 in high amounts can overstimulate CCR5, that will lead to the phosphorylation of CCR5 by CD28-induced G-protein-coupled receptor kinase 2 (GRK2). β-arrestin binds to the phosphorylated inorganic phosphate molecules. Then, β-arrestin changes its conformation and releases a site for binding to the Adaptor protein complex 2 (AP-2 complex). However, this is not enough for the AP-2 complex to join the β-arrestin. The AP-2 complex consists of four proteins called adaptins: two large adaptins (α and β), a medium adaptin (μ), and a small adaptin (σ). The α and β adaptins have so-called 'ears' that form the appendage domain. The remaining part of α and β adaptins, as well as μ and σ adaptins together form the core domain. In general, the AP-2 complex has one core domain and two appendage domains. The core domain binds to synaptotagmin ½, which is embedded in the cell membrane. It is important to know that this interaction is stable only if PIP2 is present in the cell membrane with which the AP-2 complex also binds. After the previously mentioned interactions, the AP-2 complex changes its conformation and is activated, which leads to the interaction of μ-adaptin with β-arrestin.

The cell cytosol contains clathrin protein, which consists of a heavy chain comprising three domains: proximal, distal, and N-terminal, and a light chain bound to the proximal domain of the heavy chain. Clathrin is not found as a monomer in the cell cytosol. The three clathrin molecules bind to each other using the proximal heavy chain domain to form a claritine triskelion, which is present in the cell cytosol. The claritine triskelion then binds to the appendage domains of the AP-2 complex, which will lead to polymerization of the triskelion, forming a closed three-dimensional network resembling a soccer ball. As a result of these processes, the plasma membrane is woven inward to form the Clatrin coated vesicle bud [67,68].

The cell requires Ca²⁺ for normal clathrin-dependent endocytosis. Ca²⁺ ions bind to calmodulin, forming the calmodulin/4Ca²⁺ complex. In turn, the calmodulin/4Ca²⁺ complex binds to calcineurin activating it. In the cytoplasm of the cell there is a protein dynamin 1 with which an inorganic phosphate molecule is bound and inhibiting it. Calcineurin dephosphorylates dynamin 1 and thereby activates it. Once activated, dynamin 1 binds to the "neck" of the Clatrin coated vesicle bud and oligomerizes, covering it completely. dynamin 1 has GTPase activity and having enveloped the "neck" of the clathrin coated vesicle bud it begins to hydrolyze GTP to GDP and inorganic phosphate, releasing energy which is used to enhance the torsion of oligomerized dynamin 1 around the "neck", narrowing and eventually cutting it, forming the clathrin coated endocytic vesicle. In the process of cutting the neck, endophilin also plays an important role, which is normally in the homodimerized state and also binds to the "neck" and then polymerizes around it in the form of a ring. This happens because endophilin has "+" charged amino acids, which are attracted to the "-" charged heads of the cell membrane phospholipids.

Phosphorylation of CCR5 by GRK2. β-arrestin binds with the inorganic phosphate molecules of CCR5. Then AP-2 complex binds with β-arrestin. To form a stable complex, AP-2 interacts with SYT and PIP2, embedded in the plasma membrane. Three clatrin molecules bind to each other and form clatrin triskelion. The clatrin triskelion then binds to the AP-2 complex. As a result of these processes, the plasma membrane is woven inward to form the Clatrin coated vesicle bud. Ca²⁺ ions bind to calmodulin, forming the calmodulin/4Ca²⁺ complex. The calmodulin/4Ca²⁺ complex binds to calcineurin and activates it. Calcineurin dephosphorylates dynamin 1 and thereby activates it. Once activated, dynamin 1 binds to the "neck" of the Clatrin coated vesicle bud and oligomerizes, covering it completely. Having enveloped the "neck" of the clathrin coated vesicle bud dynamin 1 begins to hydrolyze GTP to GDP and inorganic phosphate, releasing energy which is used to enhance the torsion of oligomerized dynamin 1 around the "neck", narrowing and eventually cutting it, forming the clathrin coated endocytic vesicle. Endophilin also plays an important role in forming the clathrin coated endocytic vesicle [69,70].

4. Stimulation of T-Cell Immune

Further study of the problem and analysis of the unsatisfactory results of previous years of research prompted scientists to use the T-cell immune response. In the corresponding period of time, the degree of knowledge of the virus also increased. The leading role of CD8+ T-cells in the containment of virus replication at one of the stages of its development in the body has been proven.

Subsequent studies have been conducted with increasing reliance specifically (and often, only) on the T-response [71,72]. Candidate model vaccine vectors used for T-cell vaccines were live recombinant viral vectors, mainly pox and adenovirus vectors (particularly replication-defective adenovirus 5 (Ad5)), as well as DNA vaccines [73].

STEP trial - HVTN 502 – HVTN 503 (Phambili) - recombinant replication-defective adenovirus type 5 (Ad5) vector vaccines: MRKAd5 HIV-1 gag/pol/nef clade B vaccine. Both trials were primarily aimed at reducing post-infection viral load, but were interrupted early because those who were vaccinated had an increased risk of infection [49,74,75].

HVTN 505 - DNA vaccine expressing clade B gag/pol/nef and env from branches A, B and C, which was used to prime rAd5 multiclade vaccines. The goal was to activate both arms of immunity. An increased risk of infection was not observed, but the vaccination schedule was not shown to be effective [76,77,78].

RV-144 - the study design consisted of a recombinant canarypox vector vaccine, ALVAC-HIV (vCP1521), expressing Env (branch E), group specific antigen (Gag) (branch B) and protease (Pro) (branch B), and AIDSVAX B vaccines /E with an alum adjuvant and a bivalent subunit vaccine based on HIV glycoprotein 120 (gp120). The vaccine showed significant effectiveness in protecting against HIV infection - 31.2% in 42 months after vaccination. Vaccine-induced reactions included binding of IgG antibodies to HIV Env variable loops 1 and 2 (V1V2) and antibody-dependent cellular cytotoxicity (ADCC) in low-IgA vaccine recipients. The study showed that the size and multifunctionality of Env-specific CD4+ T cells play a role in reducing the risk of HIV infection [79,80]. RV305- RV306- Evaluation of the immune response generated in recent booster vaccine recipients compared to RV144 vaccine recipients. The assumption was that late boosters will elicit a sustained immune response [80,81].

HVTN 097 - the schedule included 2 doses of ALVAC-HIV (vCP1521) HIV vaccine followed by 2 booster doses of AIDSVAX B/E. Tetanus immunization was included in the schedule to avoid cross-reaction to the vaccine [82]. The primary booster schedule induced mainly Env-specific CD4+ T cell responses at significantly higher levels compared to RV144 vaccine recipients (RV144 = 36.4%; HVTN 097 = 51.9%). IgG antibodies recognizing the V1V2 region and IgG3 binding antibody responses to gp120 and V1V2 antigens were also significantly higher among HVTN 097 vaccine recipients compared to RV144 recipients. ADCC antibody responses were also higher in HVTN 097 than in RV144 [82].

HVTN 100 is an ALVAC-HIV vector (vCP2438) expressing HIV gp120 Env (C branch of ZM96), gp41 Env, Gag and Pro (all B branches), and the bivalent protein vaccine with gp120 subtype C and MF59 adjuvant. The vaccine induced a greater frequency of IgG3 responses to Env gp120, significantly higher CD4+ T cell responses, and gp120 binding antibody responses compared to the RV144 schedule [83]. HVTN 100 exceeded levels that were modeled as necessary for protection.

HVTN 702 - evaluation of the efficacy, safety and tolerability of ALVAC-HIV (vCP2438) plus a bivalent gp120/MF59 subtype C vaccination regimen with primary booster. The vaccination schedule used in HVTN 702 has been modified to improve the efficiency and robustness of immune responses compared to RV144. The study was terminated due to the low efficacy of the vaccine [83,84].

The RV144 trial showed the best result ever for an HIV vaccine development approach, yet subsequent studies based on RV144 designed to enhance efficacy came to mixed conclusions. However, in all subsequent studies, special attention is paid to the endemicity of the HIV isolate (Table 2) [85].

5. Mosaic HIV Vaccines

Polyvalent HIV-1 Gag, Pol and Env mosaic immunogens expressed by replication-incompetent adenovirus serotype 26 (Ad26) vector and optimized to provide maximum coverage of potential T-cell epitopes. The mosaic HIV vaccine causes the formation of multifunctional antibodies - neutralizing, non-neutralizing and binding. This approach solves the problem of narrow specificity of the candidate vaccine and affects different circulating virus isolates [90]. However, large clinical studies of mosaic HIV vaccines have not shown their effectiveness, although some of these studies are currently underway (Table 3).

6. mRNA HIV Vaccine

mRNA platforms are designed to deliver a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as HIV), which the immune system will hopefully recognize and mount a defense against [103].

mRNA technology could be important in accelerating the identification of appropriate target antigens for a protective response. However, it does not resolve other challenges in HIV vaccine development, such as determining the correct antigen. B-cells play an important role in the action of these vaccines, which implement their immune response through the BCR. The mechanism of mRNA HIV vaccine is discussed below and in Figure 4.

B cell antigen receptor (BCR) is embedded in the membrane of B cells. The BCR is composed of membrane immunoglobulin (mIg) molecules and associated Igα/Igβ (CD79a/CD79b) heterodimers (α/β). The mIg subunits bind antigen, resulting in receptor aggregation, while the α/β subunits transduce signals to the cell interior. BCR aggregation rapidly activates the Src family of Lyn kinases. The cytoplasmic part of CD79a/b molecules contains immunoreceptor tyrosine-based activation motifs (ITAMs). The Lyn protein, which phosphorylates CD79a/b by the OH groups of the two tyrosine residues that make up the ITAMs, is embedded in the membrane of B cells. The Syk protein binds to the phosphorylated tyrosine residues using SRC homology 2 (SH2) domain, after which it phosphorylates itself by the OH groups of tyrosine (autophosphorylation), leading to its own activation. It is important to note that the Lyn protein can also activate Syk by phosphorylation [104].

The adaptor protein BLNK (B-cell linker protein) binds to the phosphorylated tyrosine residues of CD79a/b using the SH2 domain. Next, Syk phosphorylates the BLNK molecule by the tyrosine OH-group, facilitating the binding of phospholipase Cγ2 (PLCγ2) to it. But this is not enough to activate PLCγ2. The fact is that the Bruton's tyrosine kinase (BTK) molecule binds to the phosphorylated tyrosine residues of BLNK protein using its SH2 domain, after which BTK binds to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which is a phospholipid of the inner layer of the cell membrane using pleckstrin homology (PH) domain. The interaction of the PH domain with PIP3 leads to full activation of BTK protein. As a result, BTK phosphorylates and thereby activates PLCγ2. PLCγ2 begins to hydrolyze PIP2 (phosphotidylinositol diphosphate), which is a typical representative of cell membrane phospholipids, to inositol triphosphate (phospholipid head) and diacylglycerol (phospholipid tail). DAG remains in the cell membrane. IP3 binds to IP3 receptors located on the ER membrane and stimulates them. It is important to note that IP3 receptors are Ca²⁺ channels and that after interaction with IP3 they open, promoting the release of large amounts of Ca²⁺ ions from the ER into the cell cytosol along a concentration gradient. Ca²⁺ ions and DAG together activate PKCβ (Proteinkinase Cβ). In turn, Ca²⁺ binds to calmodulin, forming the calmodulin/4Ca²⁺ complex. In the quiescent state, the cell cytoplasm contains the molecule Nuclear factor of activated T-cells (NFAT), which is in a phosphorylated state and is a transcription factor. As long as NFAT is in the phosphorylated state it cannot pass into the nucleoplasm. The calmodulin/4Ca²⁺ complex binds to the protein calcineurine resulting in its activation. Calcineurine, a protein phosphatase, dephosphorylates NFAT and thereby changes its conformation, leading to the availability of nuclear localization signals (NLS) and transport of this transcription factor into the nucleoplasm [105].

The cell cytosol contains a caspase recruitment domain family member 11 (CARD11 or CARMA1), which is in the inactive, "closed" state. PKCβ phosphorylates CARMA1 by the serine/threonine OH-group and thereby promotes a change in the conformation of this molecule and its transition from the "closed" to the "open" state. There is a BCL10-MALT1 heterodimer (B cell CLL/lymphoma 10-MALT1 paracaspase heterodimer) in the cytoplasm. After CARMA1 is in the "open" state, it is bound to BCL10 molecule through caspase recruitment domain (CARD)-CARD domain interactions, which is a part of BCL10-MALT1 heterodimer, forming CBM signalosome complex (The caspase recruitment domain family member 11 (CARD11 or CARMA1)-B cell CLL/lymphoma 10 (BCL10)-MALT1 paracaspase (MALT1)). Once this complex is formed, the MALT1 molecule begins to oligomerize, leading to the recruitment of tumor necrosis factor receptor-associated factor 6 (TRAF6) protein, which is an E3 ubiquitin ligase. The cell cytoplasm contains the molecule IKK (IκB kinase), which consists of three subunits: IKK-α, IKK-β, and IKK-γ (NEMO-NF-kappa-B essential modulator). TRAF6 modifies IKKγ with Lys63-polyUb chains, recruiting the kinase TAK1 through its ubiquitin-binding cofactors TAB2 and TAB3. TAK1 then phosphorylates IKK-β, leading to activation of the IKK molecule. It is important to mention that the B-cell cytosol contains the NF-κb molecule, which consists of three subunits: IkBα (Inhibitor of Nuclear Factor (NF)-Κb α isoform), p50, and RelA. In the resting state, IkBα masks the NLS (nuclear localization sequence) of p50 and RelA proteins, preventing transport of these subunits as a heterodimer from the cell cytosol into the nucleoplasm. However, upon activation, IKK starts phosphorylating the IkBα subunit by the OH-groups of the serine/threonine residues. Further, the enzyme E3 ubiquitin ligase binds to the phosphorylated serine/threonine residues, promoting ubiquitination and further proteosomal degradation of IkBα. As a result, NLS is unmasked and the p50/RelA heterodimer is transferred from the cell cytoplasm into the nucleoplasm [106].

The B-cell membrane contains a CD19 protein, the intracellular part of which is phosphorylated by Lyn protein by the OH-group of tyrosine. The phosphorylated tyrosine residues of CD19 are bound to the BCAP (B cell adaptor molecule for PI3K) molecule, which recruits the p85 domain of PI3K protein to itself. This interaction leads to the activation of the p110 domain of PI3K, which with its catalytic activity phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to produce and accumulate phosphatidylinositol-3,4,5-trisphosphate (PIP3). On the one hand, PIP3 is important for binding the BTK molecule to the inner surface of the cell membrane, and on the other hand, it is important for the activation of the Akt/mTOR pathway.

BCR aggregation rapidly activates the Src family of Lyn kinases. The Lyn protein phosphorylates CD79a/b by the OH groups of the two tyrosine residues. The Syk protein binds to the phosphorylated tyrosine residues using SH2 domain, after which it phosphorylates itself by the OH groups of tyrosine (autophosphorylation), leading to its own activation. The adaptor protein BLNK binds to the phosphorylated tyrosine residues of CD79a/b using the SH2 domain. Syk phosphorylates the BLNK molecule, facilitating the binding of PLCγ2 to it. BTK molecule binds to the phosphorylated tyrosine residues of BLNK protein using its SH2 domain, after which BTK binds to PIP3 using the PH domain. As a result, BTK phosphorylates and thereby activates PLCγ2. PLCγ2 begins to hydrolyze PIP2 to IP3 and DAG. IP3 contributes to the output of Ca²⁺ from the ER. Ca²⁺ ions and DAG together activate PKCβ. Ca²⁺ binds to calmodulin, forming the calmodulin/4Ca²⁺ complex. The calmodulin/4Ca²⁺ complex binds to the protein calcineurin resulting in its activation. Calcineurin, a protein phosphatase, dephosphorylates NFAT and thereby leads to the transport of this transcription factor into the nucleoplasm. PKCβ phosphorylates CARMA1. CARMA1 binds to BCL-10 molecule, which is a part of BCL-10-MALT1 heterodimer, forming a CBM signalosome complex. Once this complex is formed, the MALT1 molecule begins to oligomerize, leading to the recruitment of TRAF6 protein. TRAF6 modifies IKKγ with Lys63-polyUb chains, recruiting the kinase TAK1 through its ubiquitin-binding cofactors TAB2 and TAB3. TAK1 then phosphorylates IKK-β, leading to activation of the IKK molecule. IKK starts phosphorylating the IkBα subunit of NF-κb. Further, the enzyme E3 ubiquitin ligase binds to the phosphate groups of IkBα, promoting ubiquitination and further proteosomal degradation of IkBα. As a result, NLS is unmasked and the p50/RelA heterodimer is transferred from the cell cytoplasm into the nucleoplasm. Intracellular part of CD19 protein is phosphorylated by Lyn. With that phosphate groups BCAP protein binds. BCAP recruits PI3K, which phosphorylates PIP2 to PIP3. On the one hand, PIP3 is important for binding the BTK molecule to the inner surface of the cell membrane, and on the other hand, it is important for the activation of the Akt/mTOR pathway [104,107].

The Table 4 below summarizes ongoing vaccine trials on the mRNA platform. The difference is in the antigens, the viral proteins that the immune system targets.

7. Dendritic Cell-Based HIV Vaccines

One of the problems of our immune system's fight against HIV is the reduced ability of professional antigen-presenting cells to present HIV antigens on their surface. This approach consists in using professional antigen presenting cells (dendritic) to activate T cells, which, in turn, are an important step in specific immune activity in both innate and adaptive pathways. To achieve this goal, antigens are targeted to dendritic cells using different strategies. The most serious trials of dendritic cell-based HIV vaccines are presented in Table 5. Most studies have been conducted on autologous DCs [111,112,113].

The great advantage of these vaccines is the activation of CTLs against HIV-infected cells, which fulfills a therapeutic role. The mechanism of CTLs activation by dendritic cells is described below and in Figure 5.

CD8+ T-cells activation plays an important role here. The CD8 glycoprotein is embedded in the Cytotoxic T-cells (CTL) membrane and its cytoplasmic part is reacted by lymphocyte-specific protein tyrosine kinase (Lck). Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG1) is also embedded in the cell membrane. PAG1 is an adaptor protein whose cytoplasmic part contains inorganic phosphate molecules. C-terminal Src kinase (CSK) interacts with the previously mentioned inorganic phosphate molecules of PAG1. Thus, PAG1 brings CSK in close proximity to the Lck molecule. CSK aids to limit Lck activity via Tyr505 phosphorylation. However, it is important to note that the Protein tyrosine phosphatase, receptor type, C (PTPRC) molecule also known as CD45 is embedded in the cell membrane. After CD8 interacts with the MHC-1 molecule on the APC membrane, CD45 is activated and begins to dephosphorylate the cytoplasmic part of PAG1, resulting in the uncoupling of CSK from the PAG1 molecule. This mechanism results in the distancing of the CSK from the cell membrane and its inability to phosphorylate and inactivate the Lck. As a result, Lck is activated and phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 (cluster of differentiation 3) by the OH group of tyrosine. This creates the opportunity for the SH2 domain of the ZAP-70 protein (Zeta-chain-associated protein kinase 70) to bind to the phosphorylated tyrosine residues. Next, Lck phosphorylates ZAP-70 by the OH-group of tyrosine, which leads to a change in its conformation and activation of the kinase domain [118,119].

The linker for activation of T cells (LAT) protein is built into the membrane of CD8+ T- cells and is a target for ZAP-70 molecule, which phosphorylates LAT on multiple tyrosine residues. The inorganic phosphates on LAT protein serve as docking sites for SH2 domains of GRB2-related adaptor protein (GADS), growth-factor receptor-bound protein 2 (GRB2), and phospholipase Cγ1 (PLCγ1).

The SH3 domain of the GRB2 is bound to the proline-rich region of the Son of Sevenless (SOS) protein, which belongs to guanine nucleotide exchange factors (GEFs). In the quiescent state in the cell cytoplasm, there is RAS protein bound to GDP-inactive state. SOS detaches the GDP molecule from RAS and attaches GTP in its place-active state. Then RAS-GTP goes to the RAF-1 protein (proto-oncogene serine/threonine-protein kinase) and activates it. In turn, RAF-1 phosphorylates and thereby activates the enzyme MEK (MAPK/ERK kinase). MEK phosphorylates the mitogen-activated protein kinase (MAPK) by the OH group of serine/threonine (mitogen-activated protein kinase) and thereby activates it. Ultimately, MAPK phosphorylates and activates specific transcription factors that increase the expression of genes responsible for cytokine synthesis [120].

The SH3-domain of the GADS protein binds to the SH2-domain-containing leukocyte protein 76 kDa (SLP76), then ZAP-70 phosphorylates SLP-76 at critical tyrosine residues. This creates binding sites for the SH2 domain of VAV and ITK (interleukin-2-inducible T-cell kinase). In turn, VAV, being GEF, serves the same function as SOS-MAPK activation.

ZAP-70 phosphorylates ITK at tyrosine residues, which leads to its activation. As we mentioned above, the inorganic phosphate on the LAT protein serves as a docking site for the SH2 domain of PLCγ1. But this is not enough to fully activate PLCγ1. ITK phosphorylates PLCγ1 at tyrosine residues, which leads to its full activation. PLCγ1 activates the inositol triphosphate system, leading to DAG formation and increased Ca²⁺ concentration in the cell. Ca²⁺ by the already known mechanism activates the NFAT pathway. DAG activates and recruits the guanyl nucleotide-releasing protein RAS (RASGRP1) into the plasma membrane. RASGRP1, like SOS, is the GEF responsible for RAS activation in T cells. RAS, in turn, as we mentioned, activates the MAPK kinase pathway. DAG, together with Ca²⁺ ions, activates PKCθ, which acts in the same way as PKCβ in B cells. This will lead to the activation of the NF-κb pathway [118,119].

Cytoplasmic part of CD8 glycoprotein binds with Lck. CSK interacts with PAG1. Thus, PAG1 brings CSK in close proximity to the Lck molecule. CSK aids to limit Lck activity via Tyr505 phosphorylation. After CD8 interacts with the MHC-1 molecule on the APC membrane, CD45 is activated and begins to dephosphorylate the cytoplasmic part of PAG1, resulting in the uncoupling of CSK from the PAG1 molecule. As a result, Lck is activated and phosphorylates the ITAMs of the CD3. Next, Lck phosphorylates and activates ZAP-70. ZAP-70 molecule phosphorylates LAT on multiple tyrosine residues. LAT protein serves as a docking site for GADS, GRB2 and PLCγ1 molecules. The SH3 domain of the GRB2 is bound to SOS. SOS converts RAS-GDP to RAS-GTP. Then RAS-GTP activates RAF-1 protein. RAF-1 activates MEK and MEK activates MAPK. Ultimately, MAPK phosphorylates and activates specific transcription factors that increase the expression of genes responsible for cytokine synthesis. GADS protein binds to the SLP-76,then ZAP-70 phosphorylates SLP-76. This creates binding sites for VAV and ITK. In turn, VAV, being GEF, serves the same function as SOS-MAPK activation. ZAP-70 phosphorylates ITK. ITK phosphorylates PLCγ1 at tyrosine residues, which leads to its full activation. PLCγ1 activates the inositol triphosphate system. Ca²⁺ activates the NFAT pathway, DAG activates and recruits the RASGRP1 into the plasma membrane. RASGRP1, like SOS, is the GEF responsible for RAS activation in T cells. DAG, together with Ca²⁺ ions, activates PKCθ [118,119].

8. Peptide-Based HIV Vaccines

The approach is to use peptides to evoke a cellular immune response against the most immunogenic or conserved regions of the target protein. This response can be elicited by naturally occurring sub-immunodominant epitopes, by employing a multi-epitope approach that allows multiple strains and different stages of the virus life cycle to be targeted at once [121,122,123,124]. The most serious trials of peptide-based HIV vaccines are presented in Table 6.

9. DNA-Based HIV Vaccines

This approach allows both humoral and cellular immune responses to be elicited using small DNA fragments encoding the antigen (plasmids). Expression of the inserted gene of interest can be controlled using a strong mammalian promoter that can be found on a plasmid backbone of bacterial DNA. When target cells are transfected with DNA vaccines, the encoded proteins will be presented in the major histocompatibility complex (MHC) [130,131,132,133,134]. The most serious trials of DNA-based HIV vaccines are presented in Table 7.

The mechanism of DNA-based HIV vaccines is described in Figure 6. These vaccines are important because they enhance the CD4+T-cell response. The fact is that MHC-II receptors with the antigen epitope are built into the membrane of the dendritic cell. Dendritic cells are approached by naive T-helpers (T0-helpers) whose membrane contains TCR and CD4. CD4 binds to MHC-II receptors, and TCR is necessary to recognize the antigen that is expressed on MHC-II. Once the antigen is recognized, the TCR transmits the signal to the T0-helper (primary signal) via CD3. Furthermore, on the surface of the T0-helper there is CD28, with which CD80/CD86, located on the surface of the dendritic cell, bind and also activate the T0-helper (secondary signal-activation). In addition, the dendritic cell secretes IL-1, which binds to IL-1R, which is on the surface of the T0-helper (tertiary activation-coactivation). As a result of all these activations, the T0-helper secretes IL-2, which acts through an autocrine mechanism. In addition to the secretion of IL-2, the T0-helper starts synthesizing and integrating the alpha chain of IL-2R into its membrane (beta and gamma chains are permanently incorporated into the T0-helper membrane), triggering the biochemical cascade discussed below [138].

Janus kinase 1 (JAK1) is associated with the cytoplasmic part of the beta chain, and Janus kinase 3 (JAK3) is associated with the cytoplasmic part of the gamma chain. In the resting state, both are inactive. It is important to know that in the heterodimerized state, IL-2Rs have low affinity for IL-2. However, after attachment of alpha chain to beta and gamma chains the affinity of IL-2R to IL-2 increases dramatically. After the interaction of IL-2R with IL-2, JAK1/JAK3 change their conformation, which leads to transphosphorylation of JAK1 and JAK3 by the OH group of tyrosine residues located in a specific site called activation loop. This phosphorylation leads to a repeated change in the conformation of JAK1 and JAK3 so that they gain affinity to the cytoplasmic part of the beta chain and begin to phosphorylate it at the OH-group of tyrosine [138].

At rest, there is a Signal transducer and activator of transcription 5 (STAT5) protein in the cytosol of the cell that binds to the phosphorylated tyrosine residues of the beta chain using its SH2 domain. Next, JAK1 and JAK3 phosphorylate STAT5 by the OH-group of tyrosine residues and detaches back from the beta chain. In the cell cytoplasm, STAT5 homodimerizes (phosphorylated tyrosine residues of STAT5 proteins bind to each other's SH2 domains). Once STAT5 is homodimerized it undergoes conformational changes and NLS appears, which plays an important role in the transport of the STAT5 homodimer from the cytosol to the nucleoplasm. STAT5 is a transcription factor that increases the expression of genes responsible for T cell proliferation. This is important because when HIV infection occurs, the pool of CD4+ T-helper cells decreases significantly, which contributes negatively to the immune system's fight against HIV [138].

After the interaction of IL-2R with IL-2, JAK1/JAK3 transphosphorylate each other. This phosphorylation leads to a change in the conformation of JAK1 and JAK3 so that they gain affinity to the cytoplasmic part of the beta chain and begin to phosphorylate it. STAT5 binds to the phosphorylated tyrosine residues of the beta chain. JAK1 and JAK3 phosphorylate STAT5. STAT5 homodimerizes and enters the nucleoplasm.

10. Viral Vector-Based HIV Vaccines

The use of viral vectors makes it possible to induce a strong cytotoxic T-lymphocyte response through intracellular antigen expression, leading to the elimination of virus-infected cells.

Vaccinia virus and adenovirus are the most used vectors mostly due to their ability to induce an immune response, specifically including CTL, to the expressed foreign antigens. The most promising trials of viral vector-based HIV vaccines are presented in Table 8.

11. Broadly Neutralizing Antibodies Against HIV

For many years, passive immunization with protective antibodies has been used in the prevention and treatment of several bacterial and viral infections, subsequently influencing the current field of HIV vaccination. The mechanism of action of antibodies through their interaction with the innate and adaptive arms of the immune system, combined with their ability to bind and neutralize infectious agents, makes the antibody-based approach attractive to researchers.

HIV spike protein, or envelope (Env) protein, plays a role in infection of human (host) cells and has high levels of sequence variation between viral strains, but neutralizing antibodies exist against semi-conserved regions. Of greatest interest for the development of HIV-1 vaccines are broadly neutralizing antibodies (bnAbs), which are effective at targeting a wide range of viral strains. Most bnAbs target key regions of HIV’s Env protein that play a role in infection of human (host) cells.

Env is synthesized as a single gp160 molecule and is post-translationally cleaved by furin to a gp120 and gp41 that form trimeric fusion protein composed of three gp120 subunits and three gp41 subunits [144,145,146]. The Env complex is anchored to the viral membrane with gp41 transmembrane domain which binds with gp120 N-terminus domain.

The gp120 structure contains several variable and conserved regions that form loops, which are key targets for bNAbs. These loops include the V1/V2, V3, V4, and V5 regions [147]. The gp120 is heavily glycosylated, and many bNAbs are glycan-dependent, meaning they recognize both the peptide backbone and the attached glycans. The specific glycosylation patterns on the loops can create or obscure epitopes for bNAbs. Many bNAbs target epitopes that are formed by the three-dimensional structure of gp120, which includes specific arrangements of the loops. These conformational epitopes can span multiple loops or regions of gp120, highlighting the importance of maintaining the structural integrity of the protein for effective antibody binding. The balance between variability and conservation in the gp120 loops determines the accessibility and effectiveness of bNAbs. While variable regions allow for immune escape, the conserved regions that form functional sites are essential for viral entry and thus remain accessible targets for bNAbs.

The data from laboratory studies on bNAbs provide grounds to suggest that developing a vaccine using these antibodies will prevent HIV infection of cells. The gp120 subunit is responsible for binding to the CD4 receptor and a co-receptor (CCR5 or CXCR4) on the host cell surface, while gp41 facilitates the fusion of the viral and host cell membranes [148]. gp120 binding to CD4 leads to large conformational changes with rearrangement of the V1V2 and V3 loops, formation of a bridging sheet and the trimer “opening” [149]. The binding of CD4 and the corresponding conformational changes in gp120 allow the binding of the coreceptor [150]. Coreceptor binding leads to activation of the gp41 fusion peptide, which brings the viral and host cell membranes into contact to complete fusion [151,152].

The V1V2 site is located at the apex of the trimeric gp120 structure. The V1 and V2 loops form beta strands, stabilized by interstrand disulfide bridges and shielded by glycans [153]. V1V2 site is involved in shielding the coreceptor-binding site and is highly variable, which contributes to immune evasion [153,154,155]. Despite its variability, certain bNAbs target a glycan-dependent epitope in this region. These bNAbs recognize the conserved elements and glycosylation patterns of the V1V2 loop and stabilize the Env trimer thereby interfering with structural changes needed for coreceptor binding [156].

The V3 glycan supersite is centrally located in the gp120 structure and is often referred to as the "crown" of gp120. It plays a critical role in coreceptor binding (CXCR4 or CCR5) and is crucial for the conformational changes required for membrane fusion [157]. V3 glycan supersite contains a highly conserved ³²⁴GDIR³²⁷ motif that is part of the CCR5 coreceptor binding site [158]. It also contains various high-mannose glycans, most notably the N332 glycan, which is binded by all known bnAbs targeting this site [159,160,161,162]. The V3 loop is a major target for bNAbs, which recognize the conserved crown region and adjacent glycans. They neutralize this epitope by disrupting coreceptor binding and restricting conformational changes in the V3 loop to activate membrane fusion mediated by gp41 [157]. The CD4 binding site (CD4bs) is a conserved region of gp120 that interacts directly with the CD4, the primary receptor for viral entry, and is essential for the virus's ability to attach to the host cells. This interaction is the first step in HIV-1 entry, making the CD4bs a critical target for neutralization. This site overlaps with the V1, V2, and V3 loops and contains a glycan shield with multiple N-linked glycans [148]. Studies have identified two types of bNAbs that bind CD4bs: CD4 mimics, which contact the CD4bs with heavy chains encoded by either VH1-2 or VH1-46, and CDRH3-dependent bNAbs, interacting with the CD4bs by their CDRH3 loop.

Among CD4 mimics, VRC01 subclass is one of the most studied bNAbs targeting the CD4bs. VRC01 subclass characterized by a V_H1-2-derived heavy chain, short CDRL1, and a 5-residue CDRL3 used to avoid clashes with the N276 glycan, present on most circulating strains [163,164].

VRC01 subclass bNAbs are generally broader and more potent than bnAbs with V_H1-46. However, recently two CD4-mimic bNAbs with V_H1-46 were identified. 1–18 and 1–55 have very high neutralization potency and breadth [165]. In addition to higher potency, 1–18 was resistant to VRC01 class escape mutations, indicating promise in potential combination therapies.

Unlike CD4 mimics, CDRH3-dependent bNAbs have different mode of binding with gp120. M1214_N1 is a newer CD4bs-targeting bNAb that binds to the CD4bs with a distinct orientation compared to CD4 mimics. M1214_N1 interacts differently with the region, utilizing its long CDRH3 loop to make deeper contacts with both the CD4bs and groove formed by the N197 and N386 glycosylation sites. The M1214_N1 epitope is centered on the CD4 binding loop and extends from V2 to V5, so called “V2V5 corridor” [166].

The gp120 "silent face" is a region on the outer domain of gp120 that is relatively inaccessible to immune recognition compared to other parts of the protein, such as the CD4bs. It is termed "silent" because it lacks the immunodominant features that typically attract a strong antibody response. The silent face is located on the opposite side of gp120 from the CD4 binding site and is covered by a dense glycan shield, which helps the virus evade immune recognition [167]. The epitope predominantly includes the N262, N295, and N448 glycans on a single gp120 monomer. By binding this epitope bNAbs can prevent conformational changes in gp120 or block interactions with host cell receptors, thereby neutralizing the virus [167].

The gp120-gp41 interface is a critical region where the two subunits of the HIV-1 Env trimer interact. This interface is responsible for maintaining the stability of the trimer and facilitating the conformational changes required for viral fusion with host cells. This region is targeted by the diverse bNAbs with different epitopes and dependency from glycans. Most of these bNAbs bind only trimeric Env protein. Their neutralization mechanisms are also different: some bnAbs, such as 8ANC195, can prevent the conformational changes required for membrane fusion [168], whereas others, such as 3BC176 and 3BC315 [169,170], destabilize the trimer by disrupting tryptophan clasps in gp41 [171].

The gp41 subunit of Env contains multiple epitopes, including the fusion peptide (FP) and membrane-proximal external region (MPER), which are both targets for bNAbs. The HIV-1 FP is one of the critical components of the virus-cell entry machinery [172]. It consists of 15-20 hydrophobic amino acid residues at the N terminus of the gp41 subunit [173]. Notably, some antibodies that interact with the gp120–gp41 interface, also bind the FP N-terminal residues, such as PGT151 [174]. The MPER is a highly conserved region of gp41 ectodomain located near the viral membrane and is also crucial for the fusion process. A feature of this epitope is that bNAbs against it recognize not only the MPER site, but also the lipid component of the viral membrane [175]. However, despite these difficulties, several antibodies binding this site and preventing the virus from merging with the host cell membrane have been identified.

Some of bNAbs targeting key regions of HIV Env protein, that play a role in infection of host cells are represented in Table 9.

To protect against HIV two or more bNAbs that target different parts of the virus are required. Combinations of bNAbs may lead to broader neutralization compared to giving bNAbs alone, and multispecific antibodies may have better efficiency than combinations. Many factors that determine effectiveness of antibody combinations exist. An alternative strategy to passive immunization with bNAbs is to use AAV-mediated gene transfer to enable in vivo production of desirable anti-HIV-1 antibodies [176,177]. The combinations of anti-HIV bNAbs under research are presented in Table 10.

The HIV-1 Env protein presents a variety of conserved epitopes that are targeted by bNAbs. The structure of Env, with its dense glycan shield and complex trimeric form, presents challenges for immune recognition but also provides multiple targets for bNAbs. These antibodies are essential for neutralizing the virus and are a central focus in efforts to develop an effective HIV vaccine.

12. Conclusions

Since none of the previously developed HIV vaccine concepts in isolation achieves a sufficient percentage of efficacy, and the combination of several types of vectors or antigens in some trials increases the possibility of achieving the goal, but does not lead to any stable result, the combinatorial approach should be applied in another direction. The key to defeating HIV may lie in the activation of several links of immunity at once, the combination of vaccine and non-vaccine approaches (pre-exposure prophylaxis, microbicides, multipurpose prevention technologies).

However, there is still a need for a vaccine - the percentage of infected medical workers, blood transfusion patients and drug users is high. Perhaps the COVID-19 pandemic and the subsequent surge in mRNA-based development will lead to significant results.